| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/22/2023 | -3.45% | Morgan Stanley | $26 → $28 | Maintains | Underweight |
| 01/06/2023 | -10.34% | Morgan Stanley | $24 → $26 | Maintains | Underweight |
| 11/03/2022 | 17.24% | Keybanc | $38 → $34 | Maintains | Overweight |
| 10/11/2022 | -17.24% | Morgan Stanley | $28 → $24 | Maintains | Underweight |
| 08/10/2022 | 31.03% | Keybanc | $41 → $38 | Maintains | Overweight |
| 07/18/2022 | -3.45% | Stifel | $37 → $28 | Maintains | Hold |
| 07/15/2022 | -3.45% | Morgan Stanley | $33 → $28 | Maintains | Underweight |
| 05/05/2022 | 13.79% | Morgan Stanley | $36 → $33 | Maintains | Underweight |
| 02/24/2022 | 41.38% | Keybanc | $47 → $41 | Maintains | Overweight |
| 01/07/2022 | 24.14% | Morgan Stanley | $37 → $36 | Maintains | Underweight |
| 08/04/2021 | 41.38% | Morgan Stanley | $45 → $41 | Maintains | Underweight |
| 08/04/2021 | 55.17% | Stephens & Co. | $60 → $45 | Downgrades | Overweight → Equal-Weight |
| 08/04/2021 | 62.07% | Keybanc | $55 → $47 | Maintains | Overweight |
| 01/08/2021 | 89.66% | Keybanc | $47 → $55 | Maintains | Overweight |
| 12/15/2020 | 55.17% | Morgan Stanley | $36 → $45 | Maintains | Underweight |
| 11/04/2020 | 24.14% | Morgan Stanley | $31 → $36 | Maintains | Underweight |
| 11/04/2020 | 62.07% | Keybanc | $43 → $47 | Maintains | Overweight |
| 08/05/2020 | 48.28% | Keybanc | $45 → $43 | Maintains | Overweight |
| 05/07/2020 | 6.9% | Morgan Stanley | $29 → $31 | Maintains | Underweight |
| 04/27/2020 | 55.17% | Keybanc | $48 → $45 | Maintains | Overweight |
| 04/13/2020 | — | Barclays | Upgrades | Underweight → Equal-Weight | |
| 04/01/2020 | 10.34% | Stifel | $35 → $32 | Maintains | Hold |
| 03/27/2020 | 0% | Morgan Stanley | $32 → $29 | Maintains | Underweight |
| 03/23/2020 | 3.45% | Stephens & Co. | $40 → $30 | Maintains | Overweight |
| 12/17/2019 | 10.34% | Morgan Stanley | $36 → $32 | Maintains | Underweight |
| 11/07/2019 | 20.69% | Stifel | $45 → $35 | Downgrades | Buy → Hold |
| 11/06/2019 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 11/06/2019 | 65.52% | Keybanc | $51 → $48 | Maintains | Overweight |
| 08/07/2019 | 65.52% | Raymond James | $57 → $48 | Maintains | Outperform |
| 02/27/2019 | 124.14% | Keybanc | $67 → $65 | Maintains | Overweight |
| 01/04/2019 | 24.14% | Barclays | $59 → $36 | Downgrades | Equal-Weight → Underweight |
| 12/18/2018 | 131.03% | Keybanc | $68 → $67 | Maintains | Overweight |
| 10/16/2018 | 137.93% | Barclays | → $69 | Initiates Coverage On | → Equal-Weight |
| 10/11/2018 | 113.79% | Morgan Stanley | $60 → $62 | Maintains | Underweight |
| 08/21/2018 | — | Raymond James | Upgrades | Market Perform → Outperform | |
| 08/08/2018 | 106.9% | Morgan Stanley | $58 → $60 | Maintains | Underweight |
| 08/08/2018 | 158.62% | Keybanc | $66 → $75 | Maintains | Overweight |
What is the target price for Avanos Medical (AVNS)?
The latest price target for Avanos Medical (NYSE: AVNS) was reported by Morgan Stanley on February 22, 2023. The analyst firm set a price target for $28.00 expecting AVNS to fall to within 12 months (a possible -3.45% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avanos Medical (AVNS)?
The latest analyst rating for Avanos Medical (NYSE: AVNS) was provided by Morgan Stanley, and Avanos Medical maintained their underweight rating.
When is the next analyst rating going to be posted or updated for Avanos Medical (AVNS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avanos Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avanos Medical was filed on February 22, 2023 so you should expect the next rating to be made available sometime around February 22, 2024.
Is the Analyst Rating Avanos Medical (AVNS) correct?
While ratings are subjective and will change, the latest Avanos Medical (AVNS) rating was a maintained with a price target of $26.00 to $28.00. The current price Avanos Medical (AVNS) is trading at is $29.00, which is out of the analyst's predicted range.